TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, announced today that clinical data featuring its Precision Cancer Monitoring℠ platform will be presented at the Next Generation Dx Summit in Washington, D.C. to be held August 18-20. The presentation, titled Urinary Circulating Free DNA Platform for Diagnosis and Cancer Treatment Monitoring will be presented by Mark Erlander, Ph.D., Trovagene’s Chief Scientific Officer.

“We continue to advance our clinical programs and present data to the medical and scientific communities demonstrating the advantages of using our urine-based molecular diagnostics in the management of various cancer types,” stated Erlander. “The data sets to be presented at this conference support the clinical utility of our non-invasive cancer monitoring tests and their ability to empower oncologists to detect and quantitatively track oncogene mutations to improve treatment decisions.”

Next Generation Dx Summit

August 19 2015, 3:30 p.m. EDT Oral Presentation
Urinary Circulating Free DNA Platform for Diagnosis and Cancer Treatment Monitoring
Presenter: Mark Erlander, Ph.D., Trovagene, Inc.

  • Urine has been shown to be a viable specimen type for cancer monitoring using liquid biopsy and offers a unique ability to track tumor dynamics
  • Several novel uses with Trovagene’s PCM platform include the ability to determine minimal residual disease after surgery, determine early response to newly initiated therapy, monitor driver mutations, monitor for resistance mutations that emerge over time, and act as an alternative to tissue biopsy
  • Data show that Trovagene’s highly sensitive, quantitative, and non-invasive assays can be used to determine the induction of tumor apoptosis and response to therapy within the first week of treatment. (Original Source)

Shares of TrovaGene Inc closed yesterday at $6.49. TROV has a 1-year high of $13.58 and a 1-year low of $3.75. The stock’s 50-day moving average is $8.45 and its 200-day moving average is $8.33.

On the ratings front, TrovaGene has been the subject of a number of recent research reports. In a report issued on August 14, Leerink Swann analyst Dan Leonard initiated coverage with a Buy rating on TROV and a price target of $9, which represents a potential upside of 38.7% from where the stock is currently trading. Separately, on July 8, Maxim Group’s Jason Kolbert reiterated a Buy rating on the stock and has a price target of $13.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Dan Leonard and Jason Kolbert have a total average return of 8.3% and -7.7% respectively. Leonard has a success rate of 57.6% and is ranked #1070 out of 3738 analysts, while Kolbert has a success rate of 33.6% and is ranked #3708.

TrovaGene Inc is a development stage molecular diagnostic company. It focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring.